Immuron Limited Faces Positive Interim Results for Travelan® in Preventing ETEC-Induced Diarrhea

Photo of author
Written By Elizabeth Monroe

Immuron Limited (ASX: IMC; NASDAQ: IMRN), a biopharmaceutical company based in Australia with a global reach, announced encouraging interim topline results regarding the effectiveness of Travelan® in preventing moderate to severe diarrhea induced by enterotoxigenic Escherichia coli (ETEC). 

The company’s ongoing clinical study marks a significant step towards developing a prophylactic treatment for travelers’ diarrhea, addressing a critical need in public health and military settings.

Background and Clinical Study Details

Immuron received funding of AU $4.8 (USD $3.43) million from the U.S. Department of Defense to conduct a phase 2 controlled human infection model (CHIM) study evaluating the efficacy of Travelan® in preventing ETEC-induced diarrhea among deployed US troops visiting developing countries. 

Credit: DepositPhotos

The study, conducted in a randomized double-blind, placebo-controlled manner, involved administering a single daily oral dose of 1200 mg of Travelan® or placebo to healthy volunteers two days prior to challenge with ETEC strain H10407, continuing for seven days.

Read More: Will Nordstrom Survive the Volatile Retail Industry? 

Interim Analysis and Key Findings

The interim analysis, encompassing data from 60 subjects who completed the inpatient challenge phase of the study, reveals promising outcomes:

  • Travelan® dosed once daily demonstrated a reduction in ETEC-induced moderate to severe diarrhea compared to placebo
  • The Travelan® group exhibited a 36.4% reduction in ETEC-induced moderate to severe diarrhea compared to the placebo group

Protective efficacy of once-daily dosing was approximately 50% as effective as the current recommended three times daily dosing regimen, showcasing strong results despite a lower-than-expected attack rate.

A noteworthy 66.7% protective efficacy against ETEC-induced severe diarrhea was observed in the Travelan® group.

Subjects in the Travelan® group showed a statistically significant reduction of 83.3% in the need for early antibiotic treatment post-challenge compared to the placebo group.

None of the subjects in the Travelan® group required intravenous rehydration post-challenge, contrasting with 100% in the placebo group.

Adverse events post-ETEC challenge were reduced by 55.6% in the Travelan® group compared to the placebo group.

Regulatory Pathway and Future Plans

Based on the positive interim results, Immuron plans to convene an end-of-phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss the pivotal phase 3 registration strategy and planned clinical trials. 

These discussions will include recommended dosing to support a Biologics License Application (BLA) for Travelan® as a prophylactic treatment for travelers’ diarrhea, a high-priority objective for the U.S. Military.

Additionally, Immuron is exploring non-dilutive funding opportunities to support the phase 3 clinical trials. 

The company’s commitment to advancing Travelan® through regulatory approval processes underscores its dedication to addressing unmet medical needs and improving public health outcomes.

Also Read: Vita Coco: Navigating the Evolving Landscape of Functional Beverages

Significant Milestone in Prophylactic Treatments  

Immuron Limited’s interim results for Travelan® represent a significant milestone in the development of prophylactic treatments for travelers’ diarrhea. 

Credit: DepositPhotos

With promising efficacy data and a clear regulatory pathway outlined, the company is poised to advance Travelan® into phase 3 clinical trials and potentially bring a much-needed solution to market. 

As the company progresses towards regulatory approval, stakeholders will closely monitor further developments and anticipate the potential impact of Travelan® on public health and military preparedness.

Read Next: Rail Vision Deploys Groundbreaking AI Safety System on National Railways Line


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at; the Financial Industry Regulatory Authority (the "FINRA") at, and relevant State Securities Administrator website and the OTC Markets website at The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: and

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.